Clinical trials: Age Related Maculopathy
Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW 2 (NCT00637377)
- Testing
- Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 189 sites in Argentina, Australia and 24 more
- Volunteers
- 1,240 people
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD)…
- Trial name
- NCT06124677
- Testing
- Faricimab
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Neovascular Age-related Macular Degeneration (nAMD)
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related…
- Trial name
- NCT06470373
- Testing
- RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
- Where
- 7 sites in United States
- Volunteers
- 434 people
- Sponsor
- Rophibio, Inc.
Age-related Macular Degeneration (AMD)
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life.
- Trial name
- MEDIAL (NCT03577041)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Age Related Macular Degeneration, AMD
Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
Efalizumab is an immunosuppressive recombinant humanized IgG1 monocolonal antibody (150 Kd) that binds to human CD11a (1) and is used for the treatment of plaque psoriasis.
- Conditions
- Age Related Macular Degeneration, AMD, CNV
- Trial name
- SEIRA (NCT00726466)
- Testing
- Efalizumab, Ranibizumab
- Where
- United States
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Age Related Macular Degeneration
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.
- Trial name
- NCT05003245
- Testing
- HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis
- Where
- 41 sites in China
- Volunteers
- 407 people
- Sponsor
- Shanghai Henlius Biotech
Geographic Atrophy, Macular Degeneration
A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)
The objectives of this study was to evaluate the safety and efficacy of avacincaptad pegol intravitreal administration in participants with geographic atrophy secondary to age-related macular degeneration (AMD)
- Trial name
- NCT04435366
- Testing
- Avacincaptad Pegol
- Where
- 205 sites in United States, Argentina and 18 more
- Volunteers
- 448 people
- Sponsor
- IVERIC bio, Inc.
Neovascular Age-related Macular Degeneration
Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).
- Trial name
- NCT04690556
- Testing
- LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Where
- 78 sites in United States, Bulgaria and 5 more
- Volunteers
- 600 people
- Sponsor
- Lupin Ltd.
Visual Impairment, Age-Related Macular Degeneration
A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training
In this study, the study team utilize virtual reality (VR) to simulate visual impairments of different types and severity in healthy subjects.
- Conditions
- Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
- Trial name
- NCT05135195
- Testing
- In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Wet Age-related Macular Degeneration (wAMD)
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration.
- Trial name
- NCT06839339
- Testing
- AL-001, Aflibercept
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
Retinal Vasculitis
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
This study will describe and estimate the incidence of Retinal Vasculitis (RV) events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea®, aflibercept 2mg) therapy in US clinical practice.
- Trial name
- NCT07105228
- Testing
- aflibercept 2mg
- Where
- United States
- Volunteers
- 290,000 people
- Sponsor
- Regeneron Pharmaceuticals
Age Related Macular Degeneration, Diabetic Macular Edema
Change in Ocular Perfusion After Intravitreal Anti-VEGF in Patients with Age-related Maculopathy or Diabetic Macula Edema
This prospective study will include patients with neovascular age-related macular degeneration or diabetic macular edema, scheduled for intravitreal aflibercept.
- Trial name
- NCT06878573
- Testing
- Intravitreal Aflibercept Injection, Laser speckle flowgraphy
- Where
- Austria
- Volunteers
- 36 people
- Sponsor
- Augenabteilung Allgemeines Krankenhaus Linz
Wet Age-related Macular Degeneration
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy
The objective of this clinical study is to evaluate the safety and feasibility of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) in patients with age related macular degeneration…
- Trial name
- ROSE (NCT00679445)
- Testing
- NeoVista Ophthalmic System
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- NeoVista
Age Related Macular Degeneration, Central Retinal Vein Occlusion
Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I
Aflibercept is FDA approved and the same molecule is available as hyperosmolar for oncology (cost 800 USD for 4ml) and isoosmolar for Ophthalmology (cost 1,770 USD for 0.05ml injection).
- Trial name
- ZIV (NCT02173873)
- Testing
- ziv-aflibercept drug
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Breast Cancer, Colorectal Cancer
Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté
Medical progress and modification of lifestyles have prolonged life expectancy, despite the development of chronic diseases. The support and care are often provided by a network of informal caregivers composed of family, friends…
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer, Alzheimer Disease
- Trial name
- ICE (NCT02626377)
- Testing
- Support provided by social worker, Information booklet receipt
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Choroidal Neovascularization, Age Related Macular Degeneration
Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at…
- Trial name
- NCT03393767
- Testing
- Ranibizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Vista Klinik
Wet Macular Degeneration
A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated.
- Trial name
- NCT03861234
- Testing
- BI 836880
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 43 people
- Sponsor
- Boehringer Ingelheim
Geographic Atrophy, Dry Age Related Macular Degeneration
Subtenon PRP Injection for Geographic Atrophy in Dry Age-Related Macular Degeneration
This study investigates the effects of subtenon autologous platelet-rich plasma (PRP) injections on retinal structure and visual function in patients with advanced dry age-related macular degeneration (AMD).
- Trial name
- GA-PRP (NCT07428798)
- Testing
- Subtenon Autologous Platelet-Rich Plasma Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Marmara University Pendik Training and Research Hospital
Age-Related Maculopathy
Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration
The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.
- Trial name
- NCT01577381
- Testing
- RN6G
- Where
- 83 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Dry Age-related Macular Degeneration
Observational Study of Vision Improvement in Late Stage Dry AMD Patients
The purpose of this study is to assess the vision improvement achieved by patients with late stage dry age-related macular degeneration who received corneal treatments by a low vision aid device.
- Trial name
- NCT04349254
- Testing
- Corneal treatment by a low vision aid device
- Where
- Canada
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Optimal Acuity Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.